Medtronic PLC (MDT) Stock AnalysisMDTMedtronic PLC

Medtronic plc is an Ireland-based healthcare technology company. The Company's technologies and therapies treat approximately 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Its product category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral Maxillofacial & Dental; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging and Urological. Its services and solutions include Ambulatory Surgery Center Resources, Digital Connectivity Information Technology (IT) Support, Equipment Services & Support, Financial Services, Innovation Lab and Office-Based Sinus Surgery. Its medical specialties include Cardiac Surgery, Electrophysiology, Gastroenterology, Hernia Repair, Interventional Cardiology and Spine Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Medtronic PLC is a good buy right now due to its current price of $94.75, which is below the average analyst price target of $99 to $110. The company has shown strong financial performance with a gross margin of 61.97% in the latest quarter and a forward P/E ratio of 14.93, indicating it is reasonably valued for growth potential. However, the RSI is at 74.88, suggesting it may be overbought in the short term, which is a risk to consider.

23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.